On 26 April of the mid-point, the Minde biodisclosure performance was recorded at 94.57 per cent in the first quarter of 2023. Proclamation shows that Minde has received approximately $372 million a quarter, a decrease of 85.53 per cent, and net profits belonging to shareholders of listed companies are approximately $7545.07 million, a decrease of 94.57 per cent. Companies indicated that the decline in demand for new coronal testing products was due mainly to a decline in the frequency of new...